Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters











Database
Language
Publication year range
1.
J Anesth ; 31(3): 374-379, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28364165

ABSTRACT

PURPOSE: Retrospective studies have associated perioperative regional anesthesia/analgesia during mastectomy for breast cancer with a decreased incidence of cancer recurrence. However, to date, no prospective data from a randomized controlled trial have been reported. In a previous study we found that extending a single-injection paravertebral block with a multiple-day perineural local anesthetic infusion improves analgesia. This follow-up study investigates the rates of cancer recurrence for the single-injection and multiple-day infusion treatments. METHODS: Patients undergoing unilateral (n = 24) or bilateral mastectomy (n = 36) were included in the study. All patients had been diagnosed with breast cancer or tumor in situ, except for six patients who were receiving prophylactic bilateral mastectomy and were excluded from analyses. Patients received unilateral or bilateral single-injection thoracic paravertebral block(s) corresponding to their surgical site(s) with ropivacaine and perineural catheter(s). Subsequently, patients were randomized to receive either ropivacaine 0.4% (n = 30) or normal saline (n = 30) via their catheter(s) until catheter removal on postoperative day 3. Cancer recurrence from the date of surgery until at least 2 years post surgery was investigated via chart review. RESULTS: Five of the 54 (9.2%) patients experienced a cancer recurrence following mastectomy-3 of 26 (11.5%) of the patients with perineural ropivacaine and 2 of 28 (7.1%) of the patients with perineural saline. CONCLUSIONS: This pilot study found no evidence that extending a single-injection paravertebral block with a multi-day perineural local anesthetic infusion decreases the risk of post-mastectomy cancer recurrence. However, due to the small sample size of this investigation, further research is needed to draw definitive conclusions.


Subject(s)
Breast Neoplasms/surgery , Mastectomy/methods , Nerve Block/methods , Pain, Postoperative/drug therapy , Adult , Amides/administration & dosage , Anesthetics, Local/administration & dosage , Double-Blind Method , Female , Follow-Up Studies , Humans , Middle Aged , Pilot Projects , Postoperative Period , Prospective Studies , Ropivacaine
2.
Anesth Analg ; 122(5): 1689-95, 2016 May.
Article in English | MEDLINE | ID: mdl-26962712

ABSTRACT

BACKGROUND: Multiple studies have demonstrated that, for single-injection popliteal sciatic nerve blocks, block characteristics are dependent upon local anesthetic injection relative to the sciatic nerve bifurcation. In contrast, this relation remains unexamined for continuous popliteal sciatic nerve blocks. We, therefore, tested the hypothesis that postoperative analgesia is improved with the perineural catheter tip at the level of the bifurcation compared with 5 cm proximal to the bifurcation. METHODS: Preoperatively, subjects having moderately painful foot or ankle surgery were randomly assigned to receive an ultrasound-guided subepimyseal perineural catheter inserted either at or 5 cm proximal to the sciatic nerve bifurcation. Subjects received a single injection of mepivacaine 1.5% either via the insertion needle preoperatively or the perineural catheter postoperatively, followed by an infusion of ropivacaine 0.2% (6 mL/h basal, 4 mL bolus, and 30-min lockout) for the study duration. The primary end point was the average pain measured on a numeric rating scale (0-10) in the 3 hours before a data collection telephone call the morning after surgery. RESULTS: The average numeric rating scale of subjects with a catheter inserted at the sciatic nerve bifurcation (n = 64) was a median (10th, 25th to 75th, and 90th quartiles) of 3.0 (0.0, 2.4-5.0, and 7.0) vs 2.0 (0.0, 1.0-4.0, and 5.0) for subjects with a catheter inserted proximal to the bifurcation (n = 64; P = 0.008). Similarly, maximum pain scores were greater in the group at the bifurcation: 6.0 (3.0, 4.4-8.0, and 9.0) vs 5.0 (0.0, 3.0-8.0, and 10.0) (P = 0.019). Differences between the groups for catheter insertion time, opioid rescue dose, degree of numbness in the foot/toes, catheter dislodgement, and fluid leakage did not reach statistical significance. CONCLUSIONS: For continuous popliteal sciatic nerve blocks, a catheter inserted 5 cm proximal to the sciatic nerve bifurcation provides superior postoperative analgesia in subjects having moderately painful foot or ankle surgery compared with catheters located at the bifurcation. This is in marked contrast with single-injection popliteal sciatic nerve blocks for which benefits are afforded to local anesthetic injection distal, rather than proximal, to the bifurcation.


Subject(s)
Amides/administration & dosage , Anesthetics, Local/administration & dosage , Catheters , Foot/surgery , Nerve Block/instrumentation , Orthopedic Procedures , Pain, Postoperative/prevention & control , Sciatic Nerve/drug effects , Adult , Amides/adverse effects , Anesthetics, Local/adverse effects , California , Female , Foot/innervation , Humans , Male , Mepivacaine/administration & dosage , Middle Aged , Nerve Block/adverse effects , Nerve Block/methods , Orthopedic Procedures/adverse effects , Pain Measurement , Pain Threshold/drug effects , Pain, Postoperative/diagnosis , Pain, Postoperative/etiology , Pain, Postoperative/physiopathology , Prospective Studies , Ropivacaine , Sciatic Nerve/diagnostic imaging , Time Factors , Treatment Outcome , Ultrasonography, Interventional
3.
Anesth Analg ; 122(5): 1681-8, 2016 May.
Article in English | MEDLINE | ID: mdl-26863502

ABSTRACT

BACKGROUND: It remains unknown whether continuous or scheduled intermittent bolus local anesthetic administration is preferable for adductor canal perineural catheters. Therefore, we tested the hypothesis that scheduled bolus administration is superior or noninferior to a continuous infusion on cutaneous knee sensation in volunteers. METHODS: Bilateral adductor canal catheters were inserted in 24 volunteers followed by ropivacaine 0.2% administration for 8 hours. One limb of each subject was assigned randomly to a continuous infusion (8 mL/h) or automated hourly boluses (8 mL/bolus), with the alternate treatment in the contralateral limb. The primary end point was the tolerance to electrical current applied through cutaneous electrodes in the distribution of the anterior branch of the medial femoral cutaneous nerve after 8 hours (noninferiority delta: -10 mA). Secondary end points included tolerance of electrical current and quadriceps femoris maximum voluntary isometric contraction strength at baseline, hourly for 14 hours, and again after 22 hours. RESULTS: The 2 administration techniques provided equivalent cutaneous analgesia at 8 hours because noninferiority was found in both directions, with estimated difference on tolerance to cutaneous current of -0.6 mA (95% confidence interval, -5.4 to 4.3). Equivalence also was found on all but 2 secondary time points. CONCLUSIONS: No evidence was found to support the hypothesis that changing the local anesthetic administration technique (continuous basal versus hourly bolus) when using an adductor canal perineural catheter at 8 mL/h decreases cutaneous sensation in the distribution of the anterior branch of the medial femoral cutaneous nerve.


Subject(s)
Amides/administration & dosage , Anesthetics, Local/administration & dosage , Femoral Nerve/drug effects , Isometric Contraction/drug effects , Muscle Strength/drug effects , Nerve Block/methods , Pain Threshold/drug effects , Quadriceps Muscle/innervation , Skin/innervation , Adult , Automation , California , Catheters , Double-Blind Method , Drug Administration Schedule , Female , Healthy Volunteers , Humans , Infusion Pumps , Infusions, Parenteral , Knee , Male , Middle Aged , Nerve Block/instrumentation , Pain Measurement , Prospective Studies , Ropivacaine , Time Factors , Transcutaneous Electric Nerve Stimulation , Young Adult
4.
Nature ; 526(7571): 118-21, 2015 Oct 01.
Article in English | MEDLINE | ID: mdl-26374997

ABSTRACT

Development of functional nanoparticles can be encumbered by unanticipated material properties and biological events, which can affect nanoparticle effectiveness in complex, physiologically relevant systems. Despite the advances in bottom-up nanoengineering and surface chemistry, reductionist functionalization approaches remain inadequate in replicating the complex interfaces present in nature and cannot avoid exposure of foreign materials. Here we report on the preparation of polymeric nanoparticles enclosed in the plasma membrane of human platelets, which are a unique population of cellular fragments that adhere to a variety of disease-relevant substrates. The resulting nanoparticles possess a right-side-out unilamellar membrane coating functionalized with immunomodulatory and adhesion antigens associated with platelets. Compared to uncoated particles, the platelet membrane-cloaked nanoparticles have reduced cellular uptake by macrophage-like cells and lack particle-induced complement activation in autologous human plasma. The cloaked nanoparticles also display platelet-mimicking properties such as selective adhesion to damaged human and rodent vasculatures as well as enhanced binding to platelet-adhering pathogens. In an experimental rat model of coronary restenosis and a mouse model of systemic bacterial infection, docetaxel and vancomycin, respectively, show enhanced therapeutic efficacy when delivered by the platelet-mimetic nanoparticles. The multifaceted biointerfacing enabled by the platelet membrane cloaking method provides a new approach in developing functional nanoparticles for disease-targeted delivery.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Blood Platelets/cytology , Cell Membrane/metabolism , Drug Delivery Systems/methods , Nanoparticles/administration & dosage , Nanoparticles/chemistry , Platelet Adhesiveness , Animals , Anti-Bacterial Agents/pharmacokinetics , Blood Vessels/cytology , Blood Vessels/metabolism , Blood Vessels/pathology , Collagen/chemistry , Collagen/immunology , Complement Activation/immunology , Coronary Restenosis/blood , Coronary Restenosis/drug therapy , Coronary Restenosis/metabolism , Disease Models, Animal , Docetaxel , Humans , Macrophages/immunology , Male , Mice , Polymers/chemistry , Rats , Rats, Sprague-Dawley , Staphylococcal Infections/blood , Staphylococcal Infections/drug therapy , Staphylococcal Infections/metabolism , Staphylococcal Infections/microbiology , Staphylococcus aureus/cytology , Staphylococcus aureus/metabolism , Taxoids/administration & dosage , Taxoids/pharmacokinetics , Unilamellar Liposomes/chemistry , Vancomycin/administration & dosage , Vancomycin/pharmacokinetics
5.
Ann Surg Oncol ; 22(6): 2017-25, 2015.
Article in English | MEDLINE | ID: mdl-25413267

ABSTRACT

BACKGROUND: In a previous randomized, triple-masked, placebo-controlled study, the authors demonstrated that extending a single-injection paravertebral nerve block with a multiple-day perineural local anesthetic infusion improves analgesia and decreases pain-related dysfunction during the 3-day infusion but not subsequent to catheter removal within 1 month after mastectomy. This report describes a prospective follow-up study of the previously published trial to investigate the possibility that extending a single-injection paravertebral block with a multiple-day infusion may decrease persistent postsurgical pain as well as pain-induced emotional and functional dysfunction 1 year after mastectomy. METHODS: Subjects undergoing uni- or bilateral mastectomy received unilateral (n = 24) or bilateral (n = 36) single-injection thoracic paravertebral block(s) with ropivacaine and perineural catheter(s). The subjects were randomized to receive either ropivacaine 0.4 % (n = 30) or normal saline (n = 30) via their catheters until the catheters were removed on postoperative day 3. Chronic pain and pain-related physical and emotional dysfunction were measured using the Brief Pain Inventory (BPI). RESULTS: No statistically significant difference between treatments 3 months after surgery was observed with the BPI. In contrast, after 12 months, only 4 subjects (13 %) who had received a perineural ropivacaine infusion reported pain-induced dysfunction compared with 14 (47 %) who had received saline infusion (P = 0.011). At 12 months, the mean BPI was 1.6 ± 4.6 for the subjects who received ropivacaine versus 5.9 ± 11.3 for the subjects who received saline (P = 0.007). CONCLUSIONS: Adding a multiple-day, continuous ropivacaine infusion to a single-injection ropivacaine paravertebral nerve block may result in a lower incidence of pain as well as pain-related physical and emotional dysfunction 1 year after mastectomy.


Subject(s)
Breast Neoplasms/psychology , Breast Neoplasms/surgery , Mastectomy/adverse effects , Nerve Block , Pain, Postoperative/etiology , Stress, Psychological/etiology , Adult , Amides/administration & dosage , Anesthetics, Local/administration & dosage , Breast Neoplasms/pathology , Female , Follow-Up Studies , Humans , Infusions, Parenteral , Middle Aged , Pain Measurement , Pain, Postoperative/drug therapy , Prognosis , Prospective Studies , Ropivacaine
6.
Reg Anesth Pain Med ; 39(2): 89-96, 2014.
Article in English | MEDLINE | ID: mdl-24448512

ABSTRACT

BACKGROUND: We aimed to determine with this randomized, triple-masked, placebo-controlled study if benefits are afforded by adding a multiple-day, ambulatory, continuous ropivacaine paravertebral nerve block to a single-injection ropivacaine paravertebral block after mastectomy. METHODS: Preoperatively, 60 subjects undergoing unilateral (n = 24) or bilateral (n = 36) mastectomy received either unilateral or bilateral paravertebral perineural catheter(s), respectively, inserted between the third and fourth thoracic transverse process(es). All subjects received an initial bolus of ropivacaine 0.5% (15 mL) via the catheter(s). Subjects were randomized to receive either perineural ropivacaine 0.4% or normal saline using portable infusion pump(s) [5 mL/h basal; 300 mL reservoir(s)]. Subjects remained hospitalized for at least 1 night and were subsequently discharged home where the catheter(s) were removed on postoperative day (POD) 3. Subjects were contacted by telephone on PODs 1, 4, 8, and 28. The primary end point was average pain (scale, 0-10) queried on POD 1. RESULTS: Average pain queried on POD 1 for subjects receiving perineural ropivacaine (n = 30) was a median (interquartile) of 2 (0-3), compared with 4 (1-5) for subjects receiving saline (n = 30; 95% confidence interval difference in medians, -4.0 to -0.3; P = 0.021]. During this same period, subjects receiving ropivacaine experienced a lower severity of breakthrough pain (5 [3-6] vs 7 [5-8]; P = 0.046) as well. As a result, subjects receiving perineural ropivacaine experienced less pain-induced physical and emotional dysfunction, as measured with the Brief Pain Inventory (lower score = less dysfunction): 14 (4-37) versus 57 (8-67) for subjects receiving perineural saline (P = 0.012). For the subscale that measures the degree of interference of pain on 7 domains, such as general activity and relationships, subjects receiving perineural saline reported a median score 10 times higher (more dysfunction) than those receiving ropivacaine (3 [0-24] vs 33 [0-44]; P = 0.035). In contrast, after infusion discontinuation, there were no statistically significant differences detected between treatment groups. CONCLUSIONS: After mastectomy, adding a multiple-day, ambulatory, continuous ropivacaine infusion to a single-injection ropivacaine paravertebral nerve block results in improved analgesia and less functional deficit during the infusion. However, no benefits were identified after infusion discontinuation.


Subject(s)
Ambulatory Care/methods , Amides/administration & dosage , Mastectomy/adverse effects , Nerve Block/methods , Pain, Postoperative/diagnosis , Pain, Postoperative/drug therapy , Adult , Double-Blind Method , Female , Humans , Infusion Pumps , Infusions, Parenteral/methods , Middle Aged , Ropivacaine , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL